CA2284099C - Detection of endometrial cancer - Google Patents
Detection of endometrial cancer Download PDFInfo
- Publication number
- CA2284099C CA2284099C CA2284099A CA2284099A CA2284099C CA 2284099 C CA2284099 C CA 2284099C CA 2284099 A CA2284099 A CA 2284099A CA 2284099 A CA2284099 A CA 2284099A CA 2284099 C CA2284099 C CA 2284099C
- Authority
- CA
- Canada
- Prior art keywords
- mmp
- uterine
- measured
- endometrial cancer
- washings
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010014759 Endometrial neoplasm Diseases 0.000 title claims abstract description 52
- 206010014733 Endometrial cancer Diseases 0.000 title claims abstract description 50
- 238000001514 detection method Methods 0.000 title claims description 19
- 238000005406 washing Methods 0.000 claims abstract description 56
- 238000000034 method Methods 0.000 claims abstract description 51
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims abstract description 33
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 48
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 48
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 32
- 101710151806 72 kDa type IV collagenase Proteins 0.000 claims description 29
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 29
- 102000004190 Enzymes Human genes 0.000 claims description 29
- 108090000790 Enzymes Proteins 0.000 claims description 29
- 230000000694 effects Effects 0.000 claims description 29
- 210000001519 tissue Anatomy 0.000 claims description 26
- 238000007805 zymography Methods 0.000 claims description 22
- 238000003556 assay Methods 0.000 claims description 21
- 238000002965 ELISA Methods 0.000 claims description 17
- 230000002357 endometrial effect Effects 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 14
- 239000000834 fixative Substances 0.000 claims description 7
- 230000000477 gelanolytic effect Effects 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 7
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 6
- 229920002866 paraformaldehyde Polymers 0.000 claims description 6
- 102000005741 Metalloproteases Human genes 0.000 claims description 5
- 108010006035 Metalloproteases Proteins 0.000 claims description 5
- 238000011084 recovery Methods 0.000 claims description 5
- 238000012544 monitoring process Methods 0.000 claims description 4
- 238000000326 densiometry Methods 0.000 claims description 3
- 210000000981 epithelium Anatomy 0.000 claims description 3
- 238000007421 fluorometric assay Methods 0.000 claims description 3
- 238000003127 radioimmunoassay Methods 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 238000012216 screening Methods 0.000 abstract description 7
- 238000005259 measurement Methods 0.000 abstract description 3
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 abstract 1
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 abstract 1
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 58
- 201000011510 cancer Diseases 0.000 description 30
- 229940088598 enzyme Drugs 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 23
- 239000000523 sample Substances 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 17
- 239000000499 gel Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 10
- 238000004393 prognosis Methods 0.000 description 9
- 102000013382 Gelatinases Human genes 0.000 description 8
- 108010026132 Gelatinases Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000009545 invasion Effects 0.000 description 8
- 230000036210 malignancy Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 208000002495 Uterine Neoplasms Diseases 0.000 description 7
- 210000005168 endometrial cell Anatomy 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 210000004291 uterus Anatomy 0.000 description 7
- 102100026639 MICOS complex subunit MIC60 Human genes 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 206010046766 uterine cancer Diseases 0.000 description 6
- 101100017533 Caenorhabditis elegans hmp-2 gene Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000004163 cytometry Methods 0.000 description 5
- 210000004696 endometrium Anatomy 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 239000005018 casein Substances 0.000 description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 4
- 235000021240 caseins Nutrition 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 238000007804 gelatin zymography Methods 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002262 irrigation Effects 0.000 description 4
- 238000003973 irrigation Methods 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000010562 histological examination Methods 0.000 description 3
- 238000009802 hysterectomy Methods 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
- 208000020584 Polyploidy Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 206010064390 Tumour invasion Diseases 0.000 description 2
- 206010046788 Uterine haemorrhage Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000002380 cytological effect Effects 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002632 myometrial effect Effects 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- GUEHESDOJBMSSE-UHFFFAOYSA-M (2-aminophenyl)mercury(1+);acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1N GUEHESDOJBMSSE-UHFFFAOYSA-M 0.000 description 1
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 208000037853 Abnormal uterine bleeding Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 238000009649 Feulgen staining Methods 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 102100030417 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 101000921780 Solanum tuberosum Cysteine synthase Proteins 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
- 102100032467 Transmembrane protease serine 13 Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003322 aneuploid effect Effects 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 108010071626 caseinase Proteins 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000010217 densitometric analysis Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003370 dye binding method Methods 0.000 description 1
- 230000032692 embryo implantation Effects 0.000 description 1
- 201000003908 endometrial adenocarcinoma Diseases 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 208000029382 endometrium adenocarcinoma Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000000765 microspectrophotometry Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57442—Specifically defined cancers of the uterus and endometrial
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
- G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
- G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPO5736A AUPO573697A0 (en) | 1997-03-20 | 1997-03-20 | Diagnosis of endometrial cancer |
| AUPO5736 | 1997-03-20 | ||
| PCT/AU1998/000189 WO1998042865A1 (en) | 1997-03-20 | 1998-03-20 | Detection of endometrial cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2284099A1 CA2284099A1 (en) | 1998-10-01 |
| CA2284099C true CA2284099C (en) | 2010-04-27 |
Family
ID=3800039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2284099A Expired - Fee Related CA2284099C (en) | 1997-03-20 | 1998-03-20 | Detection of endometrial cancer |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6607894B1 (enExample) |
| EP (1) | EP0979304B1 (enExample) |
| JP (2) | JP4183757B2 (enExample) |
| KR (1) | KR20010006344A (enExample) |
| CN (1) | CN1257550A (enExample) |
| AT (1) | ATE331039T1 (enExample) |
| AU (1) | AUPO573697A0 (enExample) |
| CA (1) | CA2284099C (enExample) |
| DE (1) | DE69835010T2 (enExample) |
| ES (1) | ES2268767T3 (enExample) |
| MY (1) | MY119567A (enExample) |
| NZ (1) | NZ337868A (enExample) |
| WO (1) | WO1998042865A1 (enExample) |
| ZA (1) | ZA982403B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11774450B2 (en) | 2020-01-21 | 2023-10-03 | Shubhendra Singh Thakur | Apparatus for detection of proteolytic activity in a biological sample |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6228596B1 (en) * | 1998-03-05 | 2001-05-08 | Diadexus, Inc. | Method of detecting and monitoring endometrial and uterine cancers |
| AUPQ219799A0 (en) | 1999-08-13 | 1999-09-02 | R. Lurie Pty Ltd | Apparatus for obtaining potological samples |
| US7071164B2 (en) | 2001-08-16 | 2006-07-04 | Kimberly-Clark Worldwide, Inc. | Anti-cancer and wound healing compounds |
| US7186693B2 (en) | 2001-08-16 | 2007-03-06 | Kimberly - Clark Worldwide, Inc. | Metalloproteinase inhibitors for wound healing |
| US7094754B2 (en) | 2001-08-16 | 2006-08-22 | Kimberly-Clark Worldwide, Inc. | Anti-aging and wound healing compounds |
| US6906036B2 (en) | 2001-08-16 | 2005-06-14 | Kimberly-Clark Worldwide, Inc. | Anti-aging and wound healing compounds |
| DE10217677A1 (de) | 2002-04-19 | 2003-11-06 | Bayer Ag | Verwendung von Aufhellern zur Herstellung von Streichmassen |
| US7148194B2 (en) | 2002-12-30 | 2006-12-12 | Kimberly-Clark Worldwide, Inc. | Method to increase fibronectin |
| US7189700B2 (en) | 2003-06-20 | 2007-03-13 | Kimberly-Clark Worldwide, Inc. | Anti-chrondrosarcoma compounds |
| US20060003391A1 (en) * | 2003-08-11 | 2006-01-05 | Ring Brian Z | Reagents and methods for use in cancer diagnosis, classification and therapy |
| US20050112622A1 (en) * | 2003-08-11 | 2005-05-26 | Ring Brian Z. | Reagents and methods for use in cancer diagnosis, classification and therapy |
| ATE463743T1 (de) * | 2004-07-23 | 2010-04-15 | Ct De Rech Public De La Sante | Überwachung von herzversagen |
| US20080131916A1 (en) * | 2004-08-10 | 2008-06-05 | Ring Brian Z | Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy |
| RU2007133660A (ru) * | 2005-02-09 | 2009-03-20 | Дженентек, Инк. (Us) | Ингибирование шеддинга her2 антагонистами матриксной металлопротеиназы |
| US7504225B2 (en) * | 2005-05-12 | 2009-03-17 | Applied Genomics, Inc. | Reagents and methods for use in cancer diagnosis, classification and therapy |
| RU2304782C1 (ru) * | 2005-12-28 | 2007-08-20 | Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М. Сеченова | Способ прогнозирования рецидива эндометриоидной кисты яичника |
| US8592393B2 (en) | 2007-11-02 | 2013-11-26 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| US8569262B2 (en) | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| WO2009059284A2 (en) | 2007-11-02 | 2009-05-07 | Momenta Pharmaceuticals, Inc. | Non-anticoagulant polysaccharide compositions |
| ES2458818T3 (es) * | 2009-04-16 | 2014-05-07 | Momenta Pharmaceuticals, Inc. | Métodos para evaluar la actividad de una composición de polisacárido |
| EP2848700B1 (en) * | 2009-07-24 | 2017-10-04 | Geadic Biotec, AIE. | Markers for endometrial cancer |
| CN102985443B (zh) | 2010-04-16 | 2017-05-10 | 动量制药公司 | 组织靶向 |
| RU2430371C1 (ru) * | 2010-04-26 | 2011-09-27 | Учреждение Российской академии наук Институт ядерной физики им. Г.И. Будкера Сибирского отделения РАН (ИЯФ СО РАН) | Способ дифференциальной диагностики и прогноза миомы и рака эндометрия |
| US10017585B2 (en) | 2010-06-17 | 2018-07-10 | Momenta Pharmaceuticals, Inc. | Methods and compositions for promoting hair growth |
| WO2012167163A2 (en) * | 2011-06-03 | 2012-12-06 | University Of South Alabama | Methods and compositions for detecting endometrial or ovarian cancer |
| AU2012312071C1 (en) * | 2011-09-22 | 2017-08-24 | Memorial Sloan-Kettering Cancer Center | Detecting ovarian cancer |
| SI2809801T1 (sl) * | 2012-01-31 | 2018-12-31 | SPEISER, Paul | Neinvazivna diagnostika raka |
| EP3003324A4 (en) | 2013-05-28 | 2017-01-25 | Momenta Pharmaceuticals, Inc. | Pharmaceutical compositions |
| US10564162B2 (en) * | 2014-07-02 | 2020-02-18 | Bionomics Limited | Predictive biomarkers |
| MX381948B (es) * | 2015-02-06 | 2025-03-13 | Quest Diagnostics Invest Llc | Composiciones y metodos para determinar el pronostico de cancer de endometrio. |
| BR112018072498A2 (pt) * | 2016-05-04 | 2019-03-12 | Fundacio Hospital Univ Vall Dhebron Institut De Recerca | marcadores de câncer do endométrio |
| CN112961921B (zh) * | 2021-03-26 | 2022-07-01 | 中国医学科学院北京协和医院 | 一种用于判断早期子宫内膜癌预后的制剂及复发风险模型 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5280106A (en) * | 1988-05-20 | 1994-01-18 | Liotta Lance A | Matrix metalloproteinase peptides: role in diagnosis and therapy |
| US5324634A (en) * | 1992-03-31 | 1994-06-28 | The Research Foundation Of State University Of New York | Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer |
| WO1994005807A1 (en) * | 1992-08-28 | 1994-03-17 | Dickson Robert B | Matrix-degrading metalloproteinase |
| EP0674710B1 (en) * | 1992-11-16 | 2003-05-02 | Cancer Research Fund Of Contra Costa | Peptides with broad neoplastic specificity |
-
1997
- 1997-03-20 AU AUPO5736A patent/AUPO573697A0/en not_active Abandoned
-
1998
- 1998-03-20 MY MYPI98001218A patent/MY119567A/en unknown
- 1998-03-20 CN CN98805312A patent/CN1257550A/zh active Pending
- 1998-03-20 NZ NZ337868A patent/NZ337868A/en not_active IP Right Cessation
- 1998-03-20 AT AT98909221T patent/ATE331039T1/de not_active IP Right Cessation
- 1998-03-20 ES ES98909221T patent/ES2268767T3/es not_active Expired - Lifetime
- 1998-03-20 ZA ZA982403A patent/ZA982403B/xx unknown
- 1998-03-20 JP JP54453698A patent/JP4183757B2/ja not_active Expired - Fee Related
- 1998-03-20 CA CA2284099A patent/CA2284099C/en not_active Expired - Fee Related
- 1998-03-20 WO PCT/AU1998/000189 patent/WO1998042865A1/en not_active Ceased
- 1998-03-20 KR KR1019997009429A patent/KR20010006344A/ko not_active Withdrawn
- 1998-03-20 DE DE69835010T patent/DE69835010T2/de not_active Expired - Lifetime
- 1998-03-20 US US09/381,454 patent/US6607894B1/en not_active Expired - Fee Related
- 1998-03-20 EP EP98909221A patent/EP0979304B1/en not_active Expired - Lifetime
-
2007
- 2007-01-09 JP JP2007001867A patent/JP2007202556A/ja not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11774450B2 (en) | 2020-01-21 | 2023-10-03 | Shubhendra Singh Thakur | Apparatus for detection of proteolytic activity in a biological sample |
Also Published As
| Publication number | Publication date |
|---|---|
| AUPO573697A0 (en) | 1997-04-10 |
| ATE331039T1 (de) | 2006-07-15 |
| CN1257550A (zh) | 2000-06-21 |
| US6607894B1 (en) | 2003-08-19 |
| DE69835010T2 (de) | 2007-06-06 |
| MY119567A (en) | 2005-06-30 |
| EP0979304A1 (en) | 2000-02-16 |
| DE69835010D1 (de) | 2006-08-03 |
| JP2007202556A (ja) | 2007-08-16 |
| WO1998042865A1 (en) | 1998-10-01 |
| ZA982403B (en) | 1998-10-21 |
| CA2284099A1 (en) | 1998-10-01 |
| EP0979304A4 (en) | 2003-06-11 |
| KR20010006344A (ko) | 2001-01-26 |
| ES2268767T3 (es) | 2007-03-16 |
| EP0979304B1 (en) | 2006-06-21 |
| JP2002501613A (ja) | 2002-01-15 |
| JP4183757B2 (ja) | 2008-11-19 |
| NZ337868A (en) | 2002-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2284099C (en) | Detection of endometrial cancer | |
| Bianco Jr et al. | Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade. | |
| Matsui et al. | Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis | |
| Moses et al. | Increased incidence of matrix metalloproteinases in urine of cancer patients | |
| US5698404A (en) | Method of predicting fetal membrane rupture based on pro-matrix metalloproteinase-9 (pro-mmp-9) | |
| JP5355086B2 (ja) | 腎細胞癌（ＲＣＣ）に対する体液性バイオマーカーとしてＭＭＰ−７を使用する、ＲＣＣを診断及びモニターするためのｉｎｖｉｔｒｏ方法 | |
| Diamandis et al. | Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients | |
| Scorilas et al. | Determination of cathepsin B expression may offer additional prognostic information for ovarian cancer patients | |
| JP5155309B2 (ja) | 患者の循環液中のＭＭＰ−７の測定を利用した転移した膀胱ガンを診断およびモニターするためのｉｎｖｉｔｒｏ方法 | |
| Diamandis et al. | Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis | |
| Sik Lee et al. | Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression | |
| Lopata et al. | Detection of endometrial cancer by determination of matrix metalloproteinases in the uterine cavity | |
| Pazhani et al. | Evaluation of salivary MMP-9 in oral squamous cell carcinoma and oral leukoplakia using ELISA | |
| JP2005527828A (ja) | 前立腺癌検出改善のための試料中の非複合体型前立腺特異抗原の分析方法 | |
| Harada et al. | Expression of matrix metalloproteinase in the fluids of renal cystic lesions | |
| JP2006311860A (ja) | 組織のリモデリングに関連した状態のための非観血的酵素スクリーン | |
| Talvensaari-Mattila et al. | Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma | |
| AU728286B2 (en) | Detection of endometrial cancer | |
| MXPA99008616A (en) | Detection of endometrial cancer | |
| US20210223245A1 (en) | Apparatus for detection of proteolytic activity in a biological sample | |
| Daher et al. | Prostate-specific antigen and new related markers for prostate cancer | |
| Bazzett et al. | Urinary matrix metalloproteinases as a potential screening test for gynecologic malignancies | |
| WO2000023613A1 (en) | A method of assessing a matter associated with parturition in a pregnant individual | |
| US20080213815A1 (en) | Diagnosing breast cancer by seprase level | |
| Vries et al. | 1826: Development of Prostate Specific Antigen Over Time in Males with Screen Detected Adenocarcinoma of the Prostate Following a Watchful Waiting Policy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20140320 |